

RECOMMENDATIONS

DIAGNOSIS

- ✓ Diagnose based on history and physical examination (Clinical features include: a seal-like barking cough, hoarseness, and often include fever, irritability, stridor and chest wall indrawing of varying severity. Children with croup should not drool or appear toxic)
- X Laboratory and radiological assessment are not routinely required
- ✓ Consider differential diagnoses:
 - Bacterial tracheitis if high fever, toxic appearance, and poor response to epinephrine
 - Epiglottitis if sudden onset of symptoms with high fever, absence of barking cough, dysphagia, drooling, anxious appearance and sitting forward in 'sniffing position'
 - Other causes of stridor: foreign body lodged in upper esophagus, retropharyngeal abscess, and hereditary angioedema

MANAGEMENT (SEE [ALGORITHM: CROUP IN THE OUT-PATIENT SETTING](#) AND [TABLE 1](#))

Drug Category	Dose and Duration	Comments
Adrenergic Agonist <ul style="list-style-type: none"> • Epinephrine 	<ul style="list-style-type: none"> • Racemic epinephrine 0.5 mL of 2.25% solution diluted in 2.5 mL of NS or sterile water via nebulizer • L Epinephrine 1:1,000 solution 5 ml via nebulizer • May be repeated back to back in children with severe respiratory distress 	<ul style="list-style-type: none"> • Racemic epinephrine and L Epinephrine are equivalent in terms of effect and safety • Racemic epinephrine is no longer readily available in North America • The duration of effect of epinephrine does not exceed two hours. This patient should not be discharged from medical care for at least two hours after receiving a dose of epinephrine. • In a child with persistent vomiting, nebulized budesonide may be combined and administered simultaneously with epinephrine
Corticosteroids <ul style="list-style-type: none"> • Dexamethasone 	<ul style="list-style-type: none"> • 0.6 mg/kg PO/IM once • May repeat dose in six to 24 hours 	<ul style="list-style-type: none"> • Oral dexamethasone is well-absorbed and achieves peak serum concentrations as rapidly as with intramuscular administration (without pain!) • Several controlled trials suggest oral and intramuscular administration yield equivalent results • Experience suggests clinical improvement will begin as early as two to three hours after treatment • Lower dose (0.15 mg/kgPO/IM) may be considered • No evidence to suggest multiple doses provide additional benefit over a single dose • Reduces: <ul style="list-style-type: none"> ○ Rate & duration of intubation ○ Rate & duration hospitalization ○ Rate of return to medical care ○ Duration of symptoms in children with mild, moderate and severe symptoms
<ul style="list-style-type: none"> • Budesonide 	<ul style="list-style-type: none"> • 0.6 mg/kg PO/IM once • May repeat dose in six to 24 hours 	<ul style="list-style-type: none"> • In the vast majority of cases, budesonide offers no advantages over dexamethasone and is substantially more expensive • May be useful in patients with vomiting, severe respiratory distress; budesonide and epinephrine can be administered simultaneously

Table 1: Pharmacology

These recommendations are systematically developed statements to assist practitioner and patient decisions about appropriate health care for specific clinical circumstances. They should be used as an adjunct to sound clinical decision making.

ALGORITHM

